Compass Pathways Stock

Compass Pathways ROE

The Return on Equity (ROE) of Compass Pathways (CMPS) as of Sep 3, 2026 is 544.70 %. In the previous year, Return on Equity (ROE) was -100.28 % — a change of -643.20% (higher).

ROE

544.70 %

YoY

-643.20%

Last updated:

In 2026, Compass Pathways's return on equity (ROE) was 544.70 %, a -643.20% increase from the -100.28 % ROE in the previous year.

The Compass Pathways ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
92.00 USD
Jan 1, 2019
-230.24 USD
Jan 1, 2020
-30.93 USD
Jan 1, 2021
-25.22 USD
Jan 1, 2022
-50.48 USD
Jan 1, 2023
-52.48 USD
Jan 1, 2024
-100.28 USD
Jan 1, 2025
544.70 USD
The Compass Pathways ROE history
YEARROEYoY
544.70 %-643.20%
-100.28 %+91.09%
-52.48 %+3.96%
-50.48 %+100.11%
-25.22 %-18.46%
-30.93 %-86.56%
-230.24 %-350.25%
92.00 %—
Access this data via the Eulerpool API
Get Free API Key

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

ROE Details

Decoding Compass Pathways's Return on Equity (ROE)

Compass Pathways's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Compass Pathways's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Compass Pathways's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Compass Pathways’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Compass Pathways stock

Return on Equity (ROE) of Compass Pathways is 544.70 % in 2026.

Return on Equity (ROE) of Compass Pathways changed from -100.28 % to 544.70 %, representing a -643.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Compass Pathways with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Compass Pathways

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Compass Pathways